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Abstract
Background: Influenza and respiratory syncytial virus (RSV) are associated with substantial morbidity and mortality in the United States. We assessed risk factors for
severe disease and medical resource utilization (MRU) among US adults hospitalized
with influenza or RSV in the Hospitalized Acute Respiratory Tract Infection (HARTI)
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study.
Methods: HARTI was a prospective global (40 centers, 12 countries) epidemiological
study of adults hospitalized with acute respiratory tract infections conducted across the
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2017–2019 epidemic seasons. Patients with confirmed influenza or RSV were followed
up to 3 months post-discharge. Baseline characteristics, prevalence of core risk factors
(CRFs) for severe disease (age ≥65 years, chronic heart or renal disease, chronic obstructive pulmonary disease, or asthma), and MRU were summarized descriptively.
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Results: The US cohort included 280 influenza-positive and 120 RSV-positive
patients. RSV patients were older (mean: 63.1 vs. 59.7 years) and a higher proportion
had CRFs (87.5% vs. 81.4%). Among those with CRFs (influenza, n = 153; RSV,
n = 99), RSV patients required longer hospitalizations (median length of stay:
4.5 days) and a greater proportion (79.8%) required oxygen supplementation during
hospitalization compared with influenza patients (4.0 days and 59.5%, respectively).
At 3 months post-discharge, a greater proportion of RSV patients with CRFs reported
use of antibiotics, antitussives, bronchodilators, and inhaled and systemic steroids
versus those with influenza and CRFs. Many patients with CRFs reported hospital
readmission at 3 months post-discharge (RSV: 13.4%; influenza: 11.9%).
Conclusions: MRU during and post-hospitalization due to RSV in adults is similar to
or greater than that of influenza. Enhanced RSV surveillance and preventive and
therapeutic interventions are needed.
KEYWORDS

hospitalization, influenza, prospective study, respiratory infections, respiratory syncytial virus,
risk factors
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$1.2 billion.20 Additionally, in a different community cohort study in

B A CKG R O U N D

New York City, among RSV-positive hospitalized adults aged
Lower respiratory tract infections (LRTIs) cause substantial morbidity

≥65 years, the majority received chest X-rays, antibiotics, and ste-

and mortality globally. In 2016, an estimated 2.38 million LRTI-

roids; the mean length of hospital stay in this population was

associated deaths occurred across all age groups worldwide.1 Influ-

6.6 days.12 Seasonal LRTI outbreaks cause significant emergency

enza and respiratory syncytial virus (RSV) are among the most com-

department utilization, crowding, and potential hospital staff short-

mon causes of LRTIs during typical (i.e., non-pandemic) endemic

ages due to infections among staff or their families.21

seasons,2 with influenza causing an estimated 1 billion infections3 and

Older adults, immunocompromised individuals, and those with

RSV causing an estimated 64 million acute respiratory infections4

underlying respiratory or cardiovascular comorbidities are at risk for

globally each year. A systematic analysis from the Global Burden of

severe influenza- or RSV-mediated disease.14,15 Detailed assessments

Diseases, Risk Factors, and Injuries study found that influenza caused

of the characteristics of adults hospitalized with influenza or RSV and

500,000 deaths and RSV caused 250,000 deaths annually world-

MRU during and post-hospitalization are lacking17; such assessments

5

wide. In the United States, there are an estimated 50,000 influenza-

are important for improving diagnostics, surveillance, prophylaxis, and

associated and 17,000 RSV-associated deaths each year.6 The annual

treatments for both pathogens.

disease burden of both influenza and RSV within the United States
7,8

The Hospitalized Acute Respiratory Tract Infection (HARTI) study

9,10

was a global study during the 2017–2019 epidemic seasons aimed at

Importantly, RSV-associated burden may be underestimated due to a

assessing risk factors for severe disease and MRU in adults hospital-

lack of routine testing for RSV and low provider awareness.11

ized with acute respiratory tract infections (ARTIs).15 We used data

varies substantially by geographic region

and endemic season.

Children (<1 year) and older adults (≥65 years) comprise the majority
12

of RSV-associated hospitalizations.

A retrospective study analyzing

from the US cohort of HARTI to assess risk factors for severe disease
and MRU in adults hospitalized with influenza or RSV.

New York City hospitalization data in infants aged <1 year and children
aged 1–4 years reported annual average influenza-associated hospitalization rates of 129.0 and 36.4 per 100,000 population and RSV-associated

2

METHODS

|

hospitalization rates of 1895.8 and 116.7 per 100,000 population, respectively.13 Influenza and RSV also cause substantial mortality in infants aged

2.1

|

Study design

<1 year (2.2 and 5.4 per 100,000 person-years, respectively) and children
aged 1–4 years (1.1 and 0.9 per 100,000 person-years, respectively).6

HARTI was a prospective cohort study in adults (≥18 years old) hospital-

Older and high-risk adults (i.e., immunocompromised individuals and

ized with ARTIs during the influenza/RSV/human metapneumovirus

those with underlying respiratory or cardiovascular comorbidities14,15)

(hMPV) season at 40 centers across 12 countries (Australia, Argentina,

also experience high RSV-associated morbidity and mortality. Hospitali-

Brazil, Canada, France, Germany, Japan, Malaysia, Mexico, Republic of

zation rates for high-risk adults of all ages infected with influenza

Korea, South Africa, and the United States) over two consecutive epi-

(242 per 100,000 population) and RSV (91 per 100,000 population) are

demic seasons (2017–2019; Figure 1). The US portion of the study was

comparable with those for older adults of all risk levels (256 and 84 per

conducted in five centers (Rochester, NY; Augusta, GA; Iowa City, IA;

100,000 population among adults aged 65–74 years, respectively).16 A

Providence, RI; and St. Louis, MO). The enrollment period was based on

prospective study of hospitalized adults in Nashville, TN, found that

local respiratory virus epidemic wave progression; US cohort patients

both influenza (11.8 per 10,000 residents) and RSV (15.0 per 10,000

were enrolled from March 07, 2017, to April 16, 2019. Patients provided

residents) cause substantial hospitalization rates among adults aged

consent and were enrolled in the study within 24 h after hospital admis-

≥50 years17; the majority of these hospitalizations are concentrated

sion. Clinical ARTI diagnoses and hospitalization decisions were made

during seasonal surges. The estimated mortality rate among US adults

according to local standard-of-care (SoC) practices. Viral testing (reverse

aged ≥65 years is 132.5 and 29.6 per 100,000 person-years for influ-

transcription polymerase chain reaction [RT-PCR]) was conducted either

enza and RSV, respectively.6

as part of SoC practices or by study-specific molecular diagnostic testing

LRTIs also require significant medical resource utilization (MRU).

with approved diagnostic platforms if not performed as part of SoC.

In the United States, influenza is responsible for an estimated 3.1 mil-

Patients with confirmed influenza, RSV, or hMPV (latter not included

lion hospitalized days, 31.4 million outpatient visits, and $87.1 billion

in this analysis due to small sample size) were invited to enroll in the

in total economic burden annually.18 A recent analysis using data from

substudy comprising a hospitalization phase (two visits: 48 h post-

published studies and public health databases estimated the average

enrollment, and within 2 days prior to discharge) and a follow-up phase

cost of influenza-associated hospitalization in the United States

with phone interviews at 1, 2, and 3 months post-discharge.

ranged from $5211 (in patients <1 year of age) to $12,102 (in patients
aged 45–64 years), depending on age group.19 There are limited data
on RSV-specific MRU. In a recent retrospective claims study among

2.2

|

Data collection

hospitalized adults in New York state, the average cost of an RSVassociated hospitalization was $8403, and the total annual cost of

Clinical information and MRU were collected through clinician-

RSV-associated hospitalizations in the United States was estimated at

reported questionnaires (at enrollment, 48 h post-enrollment, and

17502659, 2022, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/irv.12994, Wiley Online Library on [01/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

907

HARTNETT ET AL.

HARTNETT ET AL.

F I G U R E 1 Study design. ADL, activities of daily living; ARTI, acute respiratory tract infection; EQ-5D-5L, EuroQol 5 Dimensions 5 Levels;
hMPV, human metapneumovirus; IADL, instrumental activities of daily living; MRU, medical resource utilization; PCR, polymerase chain reaction;
RiiQ™, Respiratory Intensity and Impact Questionnaire; RSB, Respiratory Symptoms Bother and Change in Health Status Questionnaire; RSV,
respiratory syncytial virus; SoC, standard-of-care. †When a nasal swab was collected as part of SoC, a mid-turbinate swab was collected from the
opposite nostril and then used for the SoC test. Rapid PCR analysis was used to identify respiratory pathogens from the SoC nasal and midturbinate swabs. ‡Leftover nasal swab or blood samples were stored for potential future exploratory research. §For patients discharged within
48 h of screening, only one visit was conducted (at discharge). ¶Patient-reported questionnaires included the Barthel ADL, Lawton IADL, RiiQ™,
RSB, EQ-5D-5L, and MRU questionnaires.

within 2 days prior to discharge) and through MRU questionnaires

severe illness (low severity: 0–4; moderate: 5–6 or an individual

during monthly patient phone interviews post-discharge. If a patient

parameter scoring of 3; high: ≥7). Since all patients signed the

was discharged within 3 days of enrollment, only one hospital assess-

informed consent form for study participation, level of conscious-

ment was performed after enrollment (at discharge). Vital signs and

ness was assumed to be “Alert” (i.e., a score of 0) for all patients

complications (lower respiratory complications, cardiovascular compli-

at enrollment.

cations, bacterial superinfections, and other complications) were

Symptom severity was also assessed using a total clinical symp-

documented during hospitalization. The MRU questionnaire assessing

tom score comprising general symptom (cough, sputum production,

hospital readmissions (emergency department, general ward, or critical

shortness of breath, and malaise), lower respiratory symptom (dys-

care), the use of medical consultations (pulmonologist, respiratory

pnea; rales, rhonchi, or other abnormal breath sounds; and wheezing),

physiotherapist, or other), professional home care (general practi-

and upper respiratory symptom (nasal discharge, pharyngitis, and

tioner, nurse, respiratory physiotherapist, or other), and medications

sinus tenderness) scores, with higher scores representing more severe

taken (antibiotics, bronchodilators, inhaled steroids, systemic steroids,

disease (see Table S1). Hospital length of stay (LoS) was summarized

antitussives, oxygen, or other) was administered at 1, 2, and 3 months

and reported categorically by ≤3 or >3 days.

post-discharge.

3
2.3

|

RE SU LT S

|

Statistical analysis
3.1

|

Patients

Data collected from study questionnaires were summarized descriptively by pathogen and risk group. Patients were considered to have

The US cohort of the international HARTI study included 280 patients

core risk factors (CRFs) for progression to severe disease if they were

with influenza and 120 patients with RSV in the main study (Table 1).

aged ≥65 years or had chronic heart disease, chronic renal disease,

Patients with RSV were older (mean [standard deviation (SD)] age:

chronic obstructive pulmonary disease (COPD), or asthma.

63.1 [15.9] years) than patients with influenza (59.7 [16.9] years).

Clinical symptom severity was assessed at screening (within 24 h

Patients with RSV reported greater symptom severity at hospitaliza-

of hospitalization) using the National Early Warning Score (NEWS), a

tion as measured by NEWS (mean [SD]: 4.3 [2.6]) and total clinical

validated tool used to detect clinical deterioration in adults, which is

symptom scores (16.1 [5.6]) compared with patients with influenza

calculated using seven graded vital sign measurements (respiratory

(3.4 [2.5] and 14.9 [5.4], respectively). The majority of patients had

rate, oxygen saturation, oxygen supplementation, temperature, blood

CRFs (RSV: 87.5%; influenza: 81.4%; Figure 2A). A greater percentage

pressure, heart rate, and level of consciousness).22–25 Each vital

of patients with RSV had additional concurrent medical conditions

sign was scored from 0 to 3; NEWS scores were calculated by

during hospitalization, including acute exacerbation of asthma or

summing vital sign scores, with higher scores representing more

COPD, exacerbation of congestive heart failure (CHF), and hypoxemia
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TABLE 1

Participant demographic and baseline characteristics (main study)

Age, mean (SD), years

Influenza (n = 280)

RSV (n = 120)

59.7 (16.9)

63.1 (15.9)

18 to ≤59 years, n (%)

130 (46.4)

47 (39.2)

60 to ≤64 years, n (%)

40 (14.3)

12 (10.0)

65 to ≤74 years, n (%)

60 (21.4)

34 (28.3)

≥75 years, n (%)

50 (17.9)

27 (22.5)

Female, n (%)

149 (53.2)

Acute respiratory symptom length before
hospitalization, mean (SD), days

81 (67.5)

4.2 (4.1)

5.5 (4.8)

≤3 days, n (%)

160 (57.1)

>3 days, n (%)

120 (42.9)

70 (58.3)

n = 164

n = 75

Additional concurrent medical conditions
during hospitalization,a n (%)
Acute exacerbation of asthma or COPD

50 (41.7)

40 (24.4)

25 (33.3)

1 (0.6)

1 (1.3)

Exacerbation of congestive heart failure

27 (16.5)

17 (22.7)

Hypoxemia

41 (25.0)

26 (34.7)

Any transplantation

Malignancy or need for diagnostic workup
Sepsis
O2 supplementation at screening visit, n (%)
NEWS scale at screening,b mean (SD)
Total clinical symptom score, mean (SD)c

4 (2.4)

4 (5.3)

35 (21.3)

11 (14.7)

133 (47.5)

86 (71.7)

3.4 (2.5)

4.3 (2.6)

14.9 (5.4)

16.1 (5.6)

18 to ≤59 yearsd

14.8 (5.4)

15.1 (6.1)

60 to ≤64 years

e

16.2 (4.5)

19.2 (4.5)

65 to ≤74 yearsf

14.3 (5.8)

16.7 (5.5)

≥75 years

14.5 (5.4)

15.5 (5.1)

g

Residence pre-hospitalization, n (%)
LTCF
Private residence

2 (0.7)

4 (3.3)

256 (91.4)

110 (91.7)

Retirement community
Other

5 (1.8)

2 (1.7)

11 (3.9)

2 (1.7)

6 (2.1)

2 (1.7)

Not reported

Abbreviations: COPD, chronic obstructive pulmonary disease; LTCF, long-term care facility; NEWS, National Early Warning Score; RSV, respiratory
syncytial virus; SD, standard deviation.
a
Additional concurrent medical conditions during hospitalization are not inclusive of one another. Responses with multiple conditions were allowed.
b
Data available for 271/280 patients with influenza and 109/120 patients with RSV.
c
Data available for 273/278 patients with influenza and 119/120 patients with RSV.
d
Data available for 130/130 patients with influenza and 47/47 patients with RSV.
e
Data available for 39/40 patients with influenza and 12/12 patients with RSV.
f
Data available for 57/60 patients with influenza and 34/34 patients with RSV.
g
Data available for 47/50 patients with influenza and 26/27 patients with RSV.

(33.3%, 22.7%, and 34.7%, respectively) compared with patients with

3.2

|

MRU

influenza (24.4%, 16.5%, and 25.0%, respectively; Figure 2B). Oxygen
supplementation prior to hospitalization was only collected for

MRU during and post-hospitalization were assessed in the substudy,

patients with COPD; among these, a higher proportion of those with

which enrolled 178 and 112 patients with influenza and RSV, respec-

RSV had at-home supplemental oxygen use at baseline compared with

tively; of these, 153 patients (86.0%) with influenza and 99 patients

those with influenza (Table S2).

(88.4%) with RSV had CRFs.
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F I G U R E 2 Baseline CRFs and
ARTIs leading to hospitalization
(main study). (A) Percentage of
patients with CRFs at baseline
and (B) ARTIs reported by
patients leading to hospitalization.
ARTI, acute respiratory tract
infection; COPD, chronic
obstructive pulmonary disease;
CRF, core risk factor; RSV,
respiratory syncytial virus. †Other
ARTIs primarily consisted of viral
influenza-like ARTIs.

TABLE 2

MRU during hospitalization (substudy)
CRFsa

Length of hospital stay,b mean (SD), days
Median (range), days
≤3 days, n (%)
>3 days, n (%)
O2 supplementation given, n (%)
O2 supplementation duration, mean (SD), days
Mechanical ventilation given, n (%)

No CRFs

Influenza (n = 153)

RSV (n = 99)

Influenza (n = 25)

RSV (n = 13)

4.7 (3.0)c

5.4 (3.1)d

4.8 (4.6)

6.7 (10.1)

4 (1, 18)

4.5 (2, 17)

3 (2, 21)

3 (1, 38)

67 (43.8)

30 (30.3)

13 (52.0)

7 (53.8)

86 (56.2)

69 (69.7)

12 (48.0)

6 (46.2)

91 (59.5)

79 (79.8)

13 (52.0)

7 (53.8)

4.5 (3.6)e

4.2 (2.8)f

4.1 (4.3)g

4.2 (4.6)h

3 (2.0)

0 (0)

0 (0)

0 (0)

ICU stay during hospitalization, n (%)

8 (5.2)

8 (8.1)

ICU stay duration, mean (SD), days

4.8 (1.3)

2.5 (1.0)i

ICU stay duration, median (range), days

4.5 (3, 7)

2 (2, 4)i

1 (4.0)
3.0 ( )
3 (3, 3)

1 (7.7)
4.0 ( )
4 (4, 4)

Abbreviations: COPD, chronic obstructive pulmonary disease; CRF, core risk factor; ICU, intensive care unit; MRU, medical resource utilization; RSV,
respiratory syncytial virus; SD, standard deviation.
a
CRFs included any one or a combination of the following: age ≥65 years, chronic heart disease, COPD, chronic renal disease, and asthma.
b
Data from four subjects with censored length of hospital stay data not included in mean (SD) and median (range) results. Censored data included three
patients with influenza and CRFs (>2, >3, and >6 days) and one patient with RSV and CRFs (<3 days).
c
Data available for 150/153 patients.
d
Data available for 98/99 patients.
e
Data available for 82/91 patients given supplemental oxygen.
f
Data available for 73/79 patients given supplemental oxygen.
g
Data available for 13/13 patients given supplemental oxygen.
h
Data available for 6/7 patients given supplemental oxygen.
i
Data available for 4/8 patients with ICU stays during hospitalization.

During hospitalization, patients with RSV required greater MRU

7.7%; with CRFs: 8.1%) compared with patients with influenza (with-

compared with patients with influenza (Table 2). Regardless of the

out CRFs: 5.2%; with CRFs: 4.0%). Among patients with CRFs, those

presence of CRFs, a greater percentage of patients with RSV required

with RSV required longer hospital stays (median [range] hospital LoS:

intensive care unit (ICU) stays during hospitalization (without CRFs:

4.5 [2, 17] days) and a greater proportion (79.8%) required
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F I G U R E 3 Key MRU parameters during hospitalization. CRF, core risk factor; COPD, chronic obstructive pulmonary disease; ICU, intensive
care unit; LoS, length of stay; LTCF, long-term care facility; RSV, respiratory syncytial virus. †CRFs included any one or a combination of the
following: age ≥65 years, chronic heart disease, COPD, chronic renal disease, and asthma. ‡The one patient with influenza discharged to a LTCF
was in an LTCF prior to hospitalization. Of the eight patients with RSV who were discharged to LTCFs, four patients reported LTCF residence
prior to hospitalization.

F I G U R E 4 Medication use post-discharge (substudy). Percentage of patients reporting use of (A) antibiotics, (B) antitussives,
(C) bronchodilators, (D) inhaled steroids, (E) systemic steroids, or (F) oxygen at 1, 2, and 3 months post-discharge. CRF, core risk factor; COPD,
chronic obstructive pulmonary disease; RSV, respiratory syncytial virus. †CRFs included any one or a combination of the following: age ≥65 years,
chronic heart disease, COPD, chronic renal disease, and asthma.
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influenza

vs. 25.4%) and systemic (19.5% vs. 14.3%) steroids. Oxygen use at

(4 [1, 18] days and 59.5%, respectively). Among patients with RSV, a

3 months post-discharge was reported by similar proportions of

greater proportion of those with CRFs (79.8%) required oxygen sup-

patients with CRFs, regardless of pathogen (influenza: 19.0%; RSV:

plementation during hospitalization compared with those without

18.3%). Patients with CRFs reported substantial hospital readmission

CRFs (53.8%); among patients with influenza, similar proportions of

rates (influenza: 11.9%; RSV: 13.4%), use of medical consultations

patients required oxygen supplementation (with CRFs: 59.5%; without

(influenza: 63.5%; RSV: 59.8%), and use of professional home care

CRFs: 52.0%). A greater proportion of patients with RSV and CRFs

(influenza: 18.3%; RSV: 11.0%) at 3 months post-discharge (Figure 5).

supplemental

oxygen

compared

with

those

with

(69.7%) required hospital stays >3 days compared with patients with
influenza and CRFs (56.2%; Figure 3). Patients with RSV also experienced more complications during hospitalization, including lower

4

|

DI SCU SSION

respiratory complications, cardiovascular complications, and bacterial
superinfections, compared with patients with influenza (Figure S1).

In the US cohort of HARTI, RSV was associated with MRU compara-

In general, patients with CRFs (regardless of pathogen) reported

ble with or greater than influenza. Observations in the US cohort

more medication use at 1, 2, and 3 months post-discharge compared

reflect those in the global HARTI population; patients with RSV were

with patients without CRFs; those with RSV and CRFs generally

older and a greater proportion had CRFs compared with patients with

reported more medication use post-discharge than those with influ-

influenza.15 An analysis using data from the global HARTI study also

enza and CRFs (Figure 4). Medication use and MRU at 3 months post-

found that patients with RSV reported more severe lower respiratory

discharge were available for 126 patients with influenza and CRFs and

tract symptoms up to 3 months post-discharge compared with

82 patients with RSV and CRFs. At 3 months post-discharge, a greater

patients with influenza, in agreement with results in this study show-

proportion of patients with RSV and CRFs compared with patients

ing that patients with RSV reported greater MRU at 3 months post-

with influenza and CRFs reported use of concomitant medications

discharge compared with those with influenza.26 Additionally, results

including antibiotics (17.1% vs. 9.5%, respectively), antitussives (9.8%

from the US cohort of HARTI are also consistent with other studies

vs. 3.2%), bronchodilators (42.7% vs. 38.1%), and inhaled (39.0%

comparing the disease burden of RSV and influenza. In a

F I G U R E 5 MRU post-discharge (substudy). Percentage of patients reporting (A) hospital readmission, (B) use of medical consultations,† and
(C) professional home care‡ at 1, 2, and 3 months post-discharge. CRF, core risk factor; COPD, chronic obstructive pulmonary disease; MRU,
medical resource utilization; RSV, respiratory syncytial virus. †Medical consultations included utilization of a pulmonologist or respiratory
physiotherapist. ‡Professional home care included utilization of a general practitioner, nurse, or respiratory physiotherapist. §CRFs included any
one or a combination of the following: age ≥65 years, chronic heart disease, COPD, chronic renal disease, and asthma.
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retrospective claims study among hospitalized adults aged ≥60 years,

antibiotic use, mitigate secondary bacterial infections, and improve

Ackerson et al found that patients with RSV were older, more likely

outcomes for patients with RSV.

to have CHF and COPD at baseline, and had greater odds of requiring a hospital stay ≥7 days and ICU admission.

27

These results support efforts to improve RSV surveillance and

Another retrospec-

diagnostics as well as the development of new agents for RSV pro-

tive claims study found that, among hospitalized adults in New York

phylaxis and treatment. Development and approval of a vaccine

City, patients with RSV required a longer hospital LoS than patients

against RSV and improvements in RSV prophylaxis and therapy could

with influenza (median: 4.4 vs. 3.9 days, respectively).28 Patients with

yield similar benefits to those derived from influenza therapeutics and

RSV also more frequently experienced acute exacerbation of asthma

vaccines. A recent retrospective modeling study demonstrated that

or COPD, exacerbation of CHF, and hypoxemia; this may parallel the

universal influenza vaccination reduces the overall economic burden

association between RSV infections early in life and development of

of influenza in Canada.41 Another modeling study estimated that a 5%

bronchospastic diseases such as asthma and recurrent wheezing in

increase in influenza vaccine efficacy would prevent an additional

29,30

childhood.

1,050,000 influenza infections and 25,000 influenza-associated hospi-

Collectively, these results suggest that the severity of RSV-

talizations annually in the United States.42 Moreover, a retrospective

associated illness in adults rivals that of influenza. However, there is

US claims-based cohort study found that influenza antiviral therapy

currently no licensed RSV vaccine, and there are only two US Food

significantly decreased MRU, including hospitalizations, emergency

and Drug Administration–approved antiviral drugs for either RSV

department visits, ICU admissions, and all-cause total costs.43 These

prophylaxis (palivizumab) or treatment (ribavirin).

31

Palivizumab,

studies, in combination with the results reported here, suggest that

though effective at preventing RSV infections, is only indicated for

comparable gains could be made with improved RSV prophylaxis and

pediatric populations (specifically those aged ≤24 months32), and

therapies.

ribavirin has limited efficacy due to its non-specific antiviral activity,

This study provides key information about risk factors and MRU

constraining providers’ ability to alleviate RSV-associated disease

among US adults hospitalized with influenza or RSV and highlights the

burden.31 Two other monoclonal antibody treatments are also cur-

substantial RSV disease burden in US adults. HARTI was a prospective

rently in development; nirsevimab33,34 is currently under develop-

study conducted over two consecutive epidemic seasons, allowing

ment for use in term, pre-term, and high-risk infants, and

assessment of disease severity and MRU up to 3 months after hospital

clesrovimab35 is also being investigated for use in infants and neo-

discharge. Importantly, the 2017–2019 US epidemic seasons were

nates. In contrast, there are vaccines against influenza and four dif-

typical in terms of the number of influenza and RSV cases identified,44

ferent antiviral drugs (peramivir, zanamivir, oseltamivir phosphate,

and the results of this study were not impacted by the COVID-19

and baloxavir marboxil) approved for use in adults in the

pandemic; however, it is unclear how the pandemic and its learnings

United States.36,37

will impact patient susceptibility to influenza and RSV or MRU associ-

In this study, differences between adults hospitalized with influ-

ated with these viruses. This study has some limitations. Data on sup-

enza and those hospitalized with RSV were particularly evident among

plemental oxygen use prior to hospitalization were only collected for

patients with CRFs. Among patients with CRFs, a greater proportion

some of the patients enrolled in the study. This makes it difficult to

of those with RSV had hospital LoS >3 days, required oxygen supple-

determine the contributions of influenza or RSV disease to oxygen

mentation, and had ICU stays during hospitalization compared with

supplementation during hospitalization and post-discharge. However,

those with influenza (Figure 3). Additionally, among patients with

baseline supplemental oxygen use was recorded for participants with

CRFs, those with RSV reported equivalent or greater medication use

COPD (influenza: 25.0%; RSV: 52.3%; Table S2). During hospitaliza-

and MRU at 1, 2, and 3 months post-discharge compared with

tion, supplemental oxygen use among all patients with influenza

patients with influenza and CRFs. These findings suggest underlying

(58.4%) or RSV (76.8%) was much higher than baseline supplemental

comorbidities have a major impact on the MRU required by adults

oxygen use among those with COPD. Another limitation is the small

hospitalized with influenza or RSV.

sample size of patients without CRFs, which limits comparisons

Despite the substantial disease burden in adults, RSV is primarily

between those with versus those without CRFs. Finally, clinician-

recognized as a pediatric pathogen. RSV disease burden and MRU

reported questionnaires were not validated against patients’ medical

may be underestimated in adults due to lack of routine adult testing,

records, and patient-reported MRU was not validated against medical

low provider awareness, and the fact that RSV is often not considered

claims data.

for infections resulting in acute exacerbation of underlying respiratory

In summary, RSV infection in adults was associated with disease

or cardiovascular conditions.11 A recent prospective study in adults

burden and MRU equivalent to or greater than that of influenza. Com-

showed that point-of-care RSV testing was associated with reductions

pared with those with influenza, patients with RSV were older, more

38

possibly due to reduced unnecessary antibiotic use

likely to have CRFs, and required longer hospital stays; in particular,

and earlier initiation of supportive therapies.39 Improved RSV surveil-

among patients with CRFs, those with RSV tended to report greater

lance among adults is needed to fully evaluate the US RSV burden;

MRU and medication use than those with influenza. These results

the increased use of PCR respiratory pathogen panels in hospitals and

highlight the substantial, underappreciated disease burden of RSV in

emergency departments since the COVID-19 pandemic began may be

the United States and the need for improved RSV surveillance, pro-

useful in this regard.40 This could potentially diminish inappropriate

phylaxis, and therapies.

in hospital LoS,
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